11-week course of sequential methotrexate, thoracic irradiation, and moderate-dose cyclophosphamide for "limited"-stage small-cell bronchogenic carcinoma. A study from the Manchester Lung Tumour Group.
Thatcher, Nick Barber, Philip V Hunter, Robin D Carroll, K B Jegarajah, S Wilkinson, Peter M Crowther, Derek
Thatcher, Nick
Barber, Philip V
Hunter, Robin D
Carroll, K B
Jegarajah, S
Wilkinson, Peter M
Crowther, Derek
Citations
Altmetric:
Abstract
55 patients with inoperable but "limited"-stage small-cell carcinoma were treated sequentially with methotrexate, radiotherapy, and high doses of cyclophosphamide. The treatment was completed over 11 weeks and no maintenance chemotherapy was given. Follow-up lasted 9-29 months. Toxicity was acceptable, despite doses of cyclophosphamide of 1.5-3.5 g/m2. The complete response rate was 53%. Median survival for the total patient group was 12 months, range 2-29+. Patients who attained a complete response had a 17 month median survival; 17 patients remained in complete remission, 9 of whom first underwent treatment 14-29 months previously. Karnofsky performance scores improved after treatment and most patients were able to resume normal activity. The results are similar to those obtained with prolonged combination chemotherapy.
Affiliation
Description
Date
1982-05-08
Publisher
Collections
Keywords
Lung Cancer
Type
Article
Citation
11-week course of sequential methotrexate, thoracic irradiation, and moderate-dose cyclophosphamide for "limited"-stage small-cell bronchogenic carcinoma. A study from the Manchester Lung Tumour Group. 1982, 1 (8280):1040-3 Lancet